Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.3.1.108 (
TAT
)
2,389
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
LINGO-1 is a transmembrane receptor expressed primarily in the central nervous system (CNS) and plays an important role in myelination. Recent studies have indicated that it is also involved in oligodendrocyte precursor cell (OPC) survival and differentiation; however, the downstream signaling pathway underlying OPC development is unknown. In our previous study, we found that LINGO-1 is associated with
WNK1
in mediating Nogo-induced neurite extension inhibition by RhoA activation. In an effort to identify the role of LINGO-1-
WNK1
in OPCs, we first confirmed that
WNK1
is also expressed in OPCs and co-localized with LINGO-1, which suppresses
WNK1
expression by RNA interference-attenuated Nogo66-induced inhibition of OPC differentiation. Furthermore, we mapped the
WNK1
kinase domain using several fragmented peptides to identify the key region of interaction with LINGO-1. We found that a sequence corresponding to the D6 peptide is necessary for the interaction. Finally, we found that using the
TAT
-D6 peptide to introduce D6 peptide into primary cultured OPC inhibits the association between LINGO-1 and
WNK1
and significantly attenuates Nogo66-induced inhibition of OPC differentiation. Taken together, our results show that
WNK1
, via a specific region on
WNK1
kinase domain, interacts with LINGO-1, thus mediating Nogo66-inhibited OPC differentiation.
...
PMID:WNK1 is involved in Nogo66 inhibition of OPC differentiation. 2574 74